Sino Biopharmaceutical Limited
1177
Hisse Senetlerindeki Sıralama
#1795
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Hisse Fiyatı
$0.67161271
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$11.96B
Değişim (1 gün)
-0.38%
Değişim (1 yıl)
-28.30%
Ülke
HK
Ticaret Sino Biopharmaceutical Limited (1177)
Kategori
Healthcare
Sino Biopharmaceutical Limited (1177) için EPS
June 2026 itibariyle EPS TTM: $0.02
Sino Biopharmaceutical Limited şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $0.02'dir. 2023 yılı sonunda, şirketin EPS'si $0.01 idi; bu, 2022 yılındaki EPS olan $0.02 ile önceki yıla göre azalma.
Sino Biopharmaceutical Limited için 2000 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $0.02 | -37.33% |
| 2024 | $0.03 | 144.64% |
| 2023 | $0.01 | -29.56% |
| 2022 | $0.02 | -87.04% |
| 2021 | $0.12 | 433.48% |
| 2020 | $0.02 | -35.93% |
| 2019 | $0.04 | -49.58% |
| 2018 | $0.07 | 256.00% |
| 2017 | $0.02 | 41.84% |
| 2016 | $0.01 | 2.17% |
| 2015 | $0.01 | 17.95% |
| 2014 | $0.01 | 46.25% |
| 2013 | $0.01 | 15.94% |
| 2012 | $0.01 | 91.67% |
| 2011 | 0.00 | -20.00% |
| 2010 | 0.00 | 32.35% |
| 2009 | 0.00 | 36.00% |
| 2008 | 0.00 | 31.58% |
| 2007 | 0.00 | 58.33% |
| 2006 | 0.00 | -91.18% |
| 2005 | $0.01 | 750.00% |
| 2004 | 0.00 | 100.00% |
| 2003 | 0.00 | -66.67% |
| 2002 | 0.00 | -7.69% |
| 2001 | 0.00 | 18.18% |
| 2000 | 0.00 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $2.41 | 12,719.15% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | 2,665.96% |
US
|
